BINEX Co., Ltd. (KOSDAQ:053030)
7,850.00
-250.00 (-3.09%)
Jun 10, 2026, 3:30 PM KST
BINEX Revenue
BINEX had revenue of 35.32B KRW in the quarter ending March 31, 2026, a decrease of -11.24%. This brings the company's revenue in the last twelve months to 164.00B, up 17.04% year-over-year. In the year 2025, BINEX had annual revenue of 168.47B with 29.55% growth.
Revenue (ttm)
164.00B
Revenue Growth
+17.04%
P/S Ratio
1.57
Revenue / Employee
n/a
Employees
n/a
Market Cap
257.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 168.47B | 38.42B | 29.55% |
| Dec 31, 2024 | 130.05B | -24.77B | -16.00% |
| Dec 31, 2023 | 154.82B | -1.85B | -1.18% |
| Dec 31, 2022 | 156.68B | 22.28B | 16.58% |
| Dec 31, 2021 | 134.40B | 1.42B | 1.07% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EASY BIO,Inc. | 490.70B |
| Bioneer | 338.01B |
| GC Cell | 163.35B |
| JETEMA, | 77.07B |
| HLB Therapeutics | 67.56B |
| SillaJen | 10.92B |
| Anterogen.Co.,Ltd. | 8.06B |
| Genomictree | 3.83B |